TG THERAPEUTICS
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1993-01-01
- Employees
- 264
- Market Cap
- $3.5B
Clinical Trials
58
Trial Phases
4 Phases
Drug Approvals
1
Drug Approvals
Clinical Trials
Distribution across different clinical trial phases (55 trials with phase data)• Click on a phase to view related trials
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Participants With Relapsing Multiple Sclerosis (RMS)
- First Posted Date
- 2025-10-08
- Last Posted Date
- 2025-10-08
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 360
- Registration Number
- NCT07211633
- Locations
- 🇺🇦
TG Therapeutics Investigational Trial Site, Vinnytsia, Ukraine
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
- Conditions
- B-cell Mediated Autoimmune Disorders
- Interventions
- Drug: Azercabtagene zapreleucel (azer-cel)
- First Posted Date
- 2024-11-08
- Last Posted Date
- 2025-09-10
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 32
- Registration Number
- NCT06680037
- Locations
- 🇺🇸
TG Therapeutics Investigational Trial Site, Cleveland, Ohio, United States
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
- Conditions
- Multiple Sclerosis
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-10-01
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 728
- Registration Number
- NCT06433765
- Locations
- 🇺🇸
BRIUMVI® Pregnancy Registry Virtual Research Coordination Center, Wilmington, North Carolina, United States
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- Conditions
- Relapsing Multiple SclerosisMultiple Sclerosis
- First Posted Date
- 2024-05-30
- Last Posted Date
- 2025-10-06
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT06433752
- Locations
- 🇵🇷
TG Therapeutics Investigational Trial Site, Guaynabo, Puerto Rico
A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
- Conditions
- Relapsing Multiple Sclerosis
- First Posted Date
- 2023-11-22
- Last Posted Date
- 2025-10-06
- Lead Sponsor
- TG Therapeutics, Inc.
- Target Recruit Count
- 16
- Registration Number
- NCT06143514
- Locations
- 🇺🇸
PROVIDE Virtual Research Coordination Center, Wilmington, North Carolina, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
TG Therapeutics to Present Six-Year BRIUMVI Data at ECTRIMS 2025, Showcasing Long-Term Multiple Sclerosis Treatment Outcomes
TG Therapeutics will present six years of long-term efficacy and safety data for BRIUMVI (ublituximab-xiiy) from the ULTIMATE I and II open-label extension studies at the 2025 ECTRIMS meeting in Barcelona.
TG Therapeutics Reports 91% Revenue Surge Driven by BRIUMVI Multiple Sclerosis Treatment
TG Therapeutics reported a remarkable 91% year-over-year revenue increase in Q2 2025, primarily driven by strong sales of its multiple sclerosis treatment BRIUMVI.
TG Therapeutics Initiates Phase 3 Trial for Subcutaneous BRIUMVI in Multiple Sclerosis
TG Therapeutics has commenced enrollment in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy) for relapsing forms of multiple sclerosis, marking a significant milestone in the company's subcutaneous development program.
Roche's High-Dose Ocrevus Fails Phase 3 Trial for Multiple Sclerosis, Boosting TG Therapeutics
Roche announced that its Phase 3 MUSETTE trial testing a high-dose version of Ocrevus (ocrelizumab) failed to show additional benefit in slowing disability progression in relapsing multiple sclerosis patients.
TG Therapeutics to Present New BRIUMVI Data in Multiple Sclerosis at ACTRIMS 2025 Forum
TG Therapeutics will showcase data from ULTIMATE I & II Phase 3 trials and ENHANCE Phase 3b trial evaluating BRIUMVI in relapsing multiple sclerosis at the upcoming ACTRIMS forum in Florida.
TG Therapeutics Partners with MaxCyte to Advance Novel CAR T-Cell Therapy for Progressive MS
• TG Therapeutics has secured access to MaxCyte's flow electroporation technology to develop azercabtagene zapreleucel, an off-the-shelf CAR T-cell therapy for progressive multiple sclerosis. • The Phase 1 clinical trial will evaluate azer-cel in up to 32 patients with progressive MS forms, focusing on determining optimal dosing and safety profiles. • This innovative therapy targets CD19-expressing B-cells using donor-derived T-cells, potentially reducing MS-driving autoantibodies while avoiding graft-versus-host disease complications.
TG Therapeutics' Briumvi Exceeds Expectations, Eyes Subcutaneous Formulation and Azer-Cel Trial in MS
TG Therapeutics announced that Briumvi's 2024 sales reached $310 million, surpassing initial expectations, driven by strong adoption in relapsing forms of multiple sclerosis (RMS).
Multiple Sclerosis Pipeline Shows Promise with Novel Therapies in Development
The multiple sclerosis (MS) therapeutic landscape is expanding, with over 80 active pipeline therapies currently in development by more than 75 companies.
FDA's Accelerated Approval Pathway Faces Scrutiny as Some Drugs are Withdrawn
Several drugs approved under the FDA's accelerated approval pathway have been withdrawn from the market due to safety concerns or failure to confirm clinical benefit.
BRIUMVI Rapid Infusion Shows Promise in Multiple Sclerosis Treatment
Phase 3b ENHANCE study reveals that 30-minute infusions of BRIUMVI (ublituximab-xiiy) are well-tolerated in patients with relapsing forms of multiple sclerosis (RMS).